Brilliant Violet 605™ anti-mouse CD45.2 Anti
- 产品名称：
- Brilliant Violet 605™ anti-mouse CD45.2 Anti
- 产品类别：
- 抗体
- 产品编号：
- 109841
- 产品应用：
- 109841
- Verified Reactivity
- Mouse
- Antibody Type
- Monoclonal
- Host Species
- Mouse
- Immunogen
- B10.S mouse thymocytes and splenocytes
- Formulation
- Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and BSA (origin USA).
- Preparation
- The antibody was purified by affinity chromatography and conjugated with Brilliant Violet 605? under optimal conditions.
- Concentration
- 0.2 mg/ml
- Storage & Handling
- The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
- Application
-
FC - Quality tested
- Recommended Usage
Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤0.5 ?g per million cells in 100 ?l volume. It is recommended that the reagent be titrated for optimal performance for each application.
Brilliant Violet 605? excites at 405 nm and emits at 603 nm. The bandpass filter 610/20 nm is recommended for detection, although filter optimization may be required depending on other fluorophores used. Be sure to verify that your cytometer configuration and software setup are appropriate for detecting this channel. Refer to your instrument manual or manufacturer for support. Brilliant Violet 605? is a trademark of Sirigen Group Ltd.
Learn more about Brilliant Violet?.
This product is subject to proprietary rights of Sirigen Inc. and is made and sold under license from Sirigen Inc. The purchase of this product conveys to the buyer a non-transferable right to use the purchased product for research purposes only. This product may not be resold or incorporated in any manner into another product for resale. Any use for therapeutics or diagnostics is strictly prohibited. This product is covered by U.S. Patent(s), pending patent applications and foreign equivalents. - Excitation Laser
- Violet Laser (405 nm)
- Application Notes
The 104 antibody does not react with mouse cells expressing the CD45.1 alloantigen. Additional reported applications (for the relevant formats) include: immunoprecipitation4, in vivo and in vitro blocking of B cell responses1,2, and immunohistochemical staining of acetone-fixed frozen sections3.?
- Application References
(PubMed link indicates BioLegend citation) -
- Yakura H, et al. 1983. J. Exp. Med. 157:1077. (Block)
- Yakura H, et al. 1986. J. Immunol. 136:2729. (Block)
- Suzuki K, et al. 2000. Immunity 13:691. (IHC)
- Shen FW, et al. 1986. Immunogenetics 24:146. (IP)
- Baldwin TA and Hogquist KA. 2007. J. Immunol. 179:837.
- Pascal V, et al. 2007. J. Immunol. 179:1751.
- Burman AC, et al. 2007. Blood 110:1064.
- Kincaid EZ, et al. 2007. J. Immunol. 179:3187.
- Phan TG, et al. 2007. Nature Immunol. 8:992.
- Nakano-Yokomizo T, et al. 2011. J. Exp Med. 208:1661. PubMed
- Wen T, et al. 2013. PNAS. 110:6067. PubMed
- Kohlmeier JE, et al. 2008. Immunity. 29:101. (FC) PubMed
- Product Citations
-
- Vasanthakumar A, et al. 2020. Nature. 579:581. PubMed
- Hirai T, et al. 2020. Immunity. 54(1):84-98.e5. PubMed
- Park S, et al. 2021. Front Immunol. 11:620166. PubMed
- Inoue D, et al. 2021. Nat Genet. 53:707. PubMed
- Lee JL, et al. 2022. Aging Cell. 21:e13692. PubMed
- Yoshimi A, et al. 2019. Nature. 574:273. PubMed
- Mitchell JE, et al. 2021. Cell Reports. 35(2):108966. PubMed
- Sharma S, et al. 2015. J Immunol. 194:5529. PubMed
- Perry JSA, et al. 2018. Immunity. 48:923. PubMed
- Pauken KE, et al. 2020. Cell Reports. 31(13):107827. PubMed
- Lopez DA, et al. 2022. Cell Rep. 41:111677. PubMed
- Duan L, et al. 2021. Immunity. 54:2256. PubMed
- Watanabe K, et al. 2018. JCI Insight. 3. PubMed
- Ga?án-Gómez I, et al. 2022. Nat Med. . PubMed
- Mintz MA, et al. 2019. Immunity. 51:310. PubMed
- Deng M, et al. 2020. Nat Commun. 11:2193. PubMed
- Schadt L, et al. 2020. Cell Reports. 29(5):1236-1248.e7.. PubMed
- Camell CD, et al. 2020. Cell Metabolism. 30(6):1024-1039.e6.. PubMed
- Shi L, et al. 2016. Nat Commun. 7:12335. PubMed
- Faust HJ, et al. 2020. J Clin Invest. 130:5493. PubMed
- Jin C, et al. 2019. Cell. 176:998. PubMed
- Shen JZ, et al. 2020. Cell. 184(2):352-369.e23. PubMed
- Toshiro Hirai et al. 2019. Immunity. 50(5):1249-1261 . PubMed
- Guccini I, et al. 2020. Cancer Cell. 39(1):68-82.e9. PubMed
- Giampazolias E, et al. 2021. Cell. . PubMed
- Florez MA, et al. 2020. Cell Rep. 33:108530. PubMed
- Nelson CE et al. 2019. Cell Rep. 28(12):3092-3104 . PubMed
- Zhang Y, et al. 2019. Nat Commun. 10:3667. PubMed
- Lee SC et al. 2018. Cancer cell. 34(2):225-241 . PubMed
- Hormaechea-Agulla D, et al. 2021. Cell Stem Cell. . PubMed
- Celik H, et al. 2018. Cancer Cell. 34:741. PubMed
- Hu J, et al. 2022. J Immunother Cancer. 10:. PubMed
- Kim MY, et al. 2022. Nat Commun. 13:3296. PubMed
- RRID
- AB_2563485 (BioLegend Cat. No. 109841)
- Structure
- Protein tyrosine phosphatase (PTP) family, 180-240 kD
- Distribution
-
All hematopoietic cells except mature erythrocytes and platelets of the CD45.2 strain of mice
- Function
- Phosphatase, T and B cell activation
- Ligand/Receptor
- Galectin-1, CD2, CD3, CD4
- Biology Area
- Cell Biology, Immunology, Inhibitory Molecules, Innate Immunity, Neuroscience, Neuroscience Cell Markers
- Molecular Family
- CD Molecules
- Antigen References
-
1. Suzuki K, et al. 2000. Immunity 13:691.
- Gene ID
- 19264 View all products for this Gene ID
- UniProt
- View information about CD45.2 on UniProt.org
